PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
24 juin 2024 01h30 HE
|
PolTREG S.A.
PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
18 juin 2024 15h17 HE
|
Tevogen Bio Inc
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
14 juin 2024 07h30 HE
|
Wugen
Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
20 mai 2024 07h03 HE
|
Wugen
Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
Monthly information on share capital and company voting rights
06 mai 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
02 mai 2024 07h30 HE
|
Bio-Gene Technology Co Ltd
Guangzhou Bio-gene Technologies announces the Initiation of a Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1 in patients with AML
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
29 avr. 2024 16h46 HE
|
Cellectis Inc.
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic...
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
20 mars 2024 16h05 HE
|
Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
11 mars 2024 16h05 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
07 mars 2024 07h30 HE
|
Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...